Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TVTX

TVTX - Travere Therapeutics, Inc. Stock Price, Fair Value and News

$30.28+0.25 (+0.83%)
Market Closed

47/100

TVTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

47/100

TVTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$27.26

Target 3M

$28.88

Target 6M

$28.32

TVTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TVTX Price Action

Last 7 days

7.2%

Last 30 days

-22.1%

Last 90 days

2.1%

Trailing 12 Months

43.5%

TVTX RSI Chart

TVTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TVTX Valuation

Market Cap

2.7B

Price/Earnings (Trailing)

-30.6

Price/Sales (Trailing)

6.22

EV/EBITDA

-85.95

Price/Free Cashflow

-42.75

TVTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$27.26

Target 3M

$28.88

Target 6M

$28.32

TVTX Fundamentals

TVTX Revenue

Revenue (TTM)

435.8M

Rev. Growth (Yr)

162.11%

Rev. Growth (Qtr)

44.05%

TVTX Earnings

Earnings (TTM)

-88.5M

Earnings Growth (Yr)

146.9%

Earnings Growth (Qtr)

301.54%

TVTX Profitability

EBT Margin

-20.32%

Return on Equity

-120.36%

Return on Assets

-16.44%

Free Cashflow Yield

-2.34%

TVTX Investor Care

Shares Dilution (1Y)

14.63%

Diluted EPS (TTM)

-1.04

TVTX Alerts

  • 6 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025273.5M333.9M435.8M0
2024155.7M177.6M203.4M233.2M
2023116.9M120.5M129.5M145.2M
2022126.2M120.6M115.1M109.5M
2021198.0M204.1M221.2M131.8M
2020183.5M187.3M194.0M198.3M
2019165.4M168.8M172.4M175.3M
2018159.7M162.3M162.7M164.2M
2017138.2M143.7M150.1M154.9M
2016111.5M120.8M126.7M133.6M
201545.5M63.9M83.5M99.9M
20147.3M14.3M21.2M28.2M
20136.8M4.7M2.5M360.0K
20120009.0M
20110000
Get all data in R, Python etc through our Historical Stock Data APIs

About Travere Therapeutics, Inc.

TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
 CEO
 WEBSITEtravere.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES462

Travere Therapeutics, Inc. Frequently Asked Questions

TVTX is the stock ticker symbol of Travere Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Travere Therapeutics, Inc. is 2.71 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check TVTX's fair value in chart for subscribers.

The fair value guage provides a quick view whether TVTX is over valued or under valued. Whether Travere Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Travere Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TVTX.

As of Wed Jan 28 2026, TVTX's PE ratio (Price to Earnings) is -30.6 and Price to Sales (PS) ratio is 6.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TVTX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Travere Therapeutics, Inc. has provided 0.073 (multiply by 100 for percentage) rate of return.